163 related articles for article (PubMed ID: 16982466)
1. Four primary malignancies successively occurred in a BRCA2 mutation carrier: a case report.
Fruscalzo A; Damante G; Calcagno A; Di Loreto C; Marchesoni D
Cancer Invest; 2006 Oct; 24(6):611-4. PubMed ID: 16982466
[TBL] [Abstract][Full Text] [Related]
2. [Management of gynecological tumors associated with BRCA1 and BRCA2 germline mutations. Case report and literature review].
Fruscalzo A; Lellé RJ; Calcagno A; Driul L; Damante G; Marchesoni D
Minerva Ginecol; 2006 Apr; 58(2):171-5. PubMed ID: 16582871
[TBL] [Abstract][Full Text] [Related]
3. Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome?
Goshen R; Chu W; Elit L; Pal T; Hakimi J; Ackerman I; Fyles A; Mitchell M; Narod SA
Gynecol Oncol; 2000 Dec; 79(3):477-81. PubMed ID: 11104623
[TBL] [Abstract][Full Text] [Related]
4. Three primary malignancies related to BRCA mutation successively occurring in a BRCA1 185delAG mutation carrier.
Piura B; Rabinovich A; Yanai-Inbar I
Eur J Obstet Gynecol Reprod Biol; 2001 Aug; 97(2):241-4. PubMed ID: 11451557
[TBL] [Abstract][Full Text] [Related]
5. BRCA2 germline mutation in a woman with uterine serous papillary carcinoma--case report.
Lavie O; Ben-Arie A; Pilip A; Rennert G; Cohen Y; Feiner B; Auslnader R
Gynecol Oncol; 2005 Nov; 99(2):486-8. PubMed ID: 16051327
[TBL] [Abstract][Full Text] [Related]
6. Mixed ovarian germ cell tumor in a BRCA2 mutation carrier.
Hamel N; Wong N; Alpert L; Galvez M; Foulkes WD
Int J Gynecol Pathol; 2007 Apr; 26(2):160-4. PubMed ID: 17413983
[TBL] [Abstract][Full Text] [Related]
7. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
[TBL] [Abstract][Full Text] [Related]
8. Familial papillary serous carcinoma of the cervix, peritoneum, and ovary: a report of the first case.
Kaplan EJ; Caputo TA; Shen PU; Sassoon RI; Soslow RA
Gynecol Oncol; 1998 Aug; 70(2):289-94. PubMed ID: 9740708
[TBL] [Abstract][Full Text] [Related]
9. Concomitant BRCA1 and BRCA2 gene mutations in an Ashkenazi Jewish woman with primary breast and ovarian cancer.
Spannuth WA; Thaker PH; Sood AK
Am J Obstet Gynecol; 2007 Apr; 196(4):e6-9. PubMed ID: 17403394
[TBL] [Abstract][Full Text] [Related]
10. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
Rabban JT; Barnes M; Chen LM; Powell CB; Crawford B; Zaloudek CJ
Am J Surg Pathol; 2009 Aug; 33(8):1125-36. PubMed ID: 19440148
[TBL] [Abstract][Full Text] [Related]
11. Hereditary breast/ovarian cancer: clinicopathological characteristics and survival of BRCA2 positive and negative cases.
Syamala V; Syamala VS; Sreeja L; Raveendran PB; Vijayalekshmi RV; Sheeja VR; Santhi S; Kuttan R; Abraham EK; Ankathil R
J Exp Ther Oncol; 2008; 7(3):227-36. PubMed ID: 19066131
[TBL] [Abstract][Full Text] [Related]
12. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
13. High frequency of BRCA1/2 germline mutations in consecutive ovarian cancer patients in Poland.
Brozek I; Ochman K; Debniak J; Morzuch L; Ratajska M; Stepnowska M; Stukan M; Emerich J; Limon J
Gynecol Oncol; 2008 Feb; 108(2):433-7. PubMed ID: 17997147
[TBL] [Abstract][Full Text] [Related]
14. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
15. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.
Kauff ND; Barakat RR
J Clin Oncol; 2007 Jul; 25(20):2921-7. PubMed ID: 17617523
[TBL] [Abstract][Full Text] [Related]
16. Multicentric glioblastoma multiforme in a patient with BRCA-1 invasive breast cancer.
Elmariah SB; Huse J; Mason B; Leroux P; Lustig RA
Breast J; 2006; 12(5):470-4. PubMed ID: 16958968
[TBL] [Abstract][Full Text] [Related]
17. No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers.
Rashid MU; Torres D; Zaidi A; Rasheed F; Sultan F; Shakoori AR; Amin A; Hamann U
Breast Cancer Res Treat; 2008 Jan; 107(1):155-6. PubMed ID: 18043900
[No Abstract] [Full Text] [Related]
18. BRCA mutations and the risk of angiosarcoma after breast cancer treatment.
West JG; Weitzel JN; Tao ML; Carpenter M; West JE; Fanning C
Clin Breast Cancer; 2008 Dec; 8(6):533-7. PubMed ID: 19073510
[TBL] [Abstract][Full Text] [Related]
19. BRCA2 mutation screening is clinically relevant in breast and early prostate cancer families.
Azzouzi AR; Stoppa-Lyonnet D; Roupret M; Larre S; Mangin P; Cussenot O
Int J Urol; 2007 May; 14(5):445-6. PubMed ID: 17511731
[TBL] [Abstract][Full Text] [Related]
20. BRCA2 mutations as a universal risk factor for pancreatic cancer has a limited role in Korean ethnic group.
Cho JH; Bang S; Park SW; Chung JB; Song SY
Pancreas; 2008 May; 36(4):337-40. PubMed ID: 18437078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
